MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

FibroGen Inc

Închisă

SectorSănătate

0.3 3.45

Rezumat

Modificarea prețului

24h

Curent

Minim

0.28

Maxim

0.3

Indicatori cheie

By Trading Economics

Venit

35M

18M

Vânzări

-170M

-123M

EPS

-0.08

Marjă de profit

-14.589

Angajați

225

EBITDA

-74M

-91M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+3125.81% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-13M

32M

Deschiderea anterioară

-3.15

Închiderea anterioară

0.3

Sentimentul știrilor

By Acuity

55%

45%

324 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

FibroGen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 feb. 2025, 11:34 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb. 2025, 11:34 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb. 2025, 11:33 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb. 2025, 11:33 UTC

Achiziții, Fuziuni, Preluări

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb. 2025, 11:31 UTC

Achiziții, Fuziuni, Preluări

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb. 2025, 11:30 UTC

Achiziții, Fuziuni, Preluări

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Comparație

Modificare preț

FibroGen Inc Așteptări

Obiectiv de preț

By TipRanks

3125.81% sus

Prognoză pe 12 luni

Medie 10 USD  3125.81%

Maxim 10 USD

Minim 10 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFibroGen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.3 / 0.3416Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

324 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.